文献速递耳科与耳神经

囊性纤维化患者接受胃肠外氨基糖苷类治疗后的进行性听力损失

Progressive Hearing Loss among Patients with Cystic Fibrosis and Parenteral Aminoglycoside Treatment.
PubMed 文献 · Otolaryngol Head Neck Surg · 2018-06-19

该回顾性病例回顾比较了165例成人囊性纤维化(CF)患者10年间的首末次听力图,按静脉氨基糖苷类抗生素(IVs)使用次数分为0次、1-9次和≥10次三组。首次检查时48%已有听力损失,末次检查时64%有听力损失(即使经年龄/性别校正);1-9次组48%和≥10次组近80%出现耳毒性评分。结论是多数成人CF患者反复暴露于胃肠外氨基糖苷类,听力损失速度远超单纯老化预测。

要点

  • 成人CF患者首次听力检查时48%已有听力损失。
  • 末次检查时64%有听力损失,经年龄/性别校正后仍显著。
  • ≥10次静脉氨基糖苷类暴露者近80%出现耳毒性评分。

核心结论

  • 多数成人CF患者反复暴露于胃肠外氨基糖苷类,听力损失速度远超单纯老化预测。

研究设计与样本

  • 回顾性病例回顾,比较165例成人CF患者10年间首末次听力图。
  • 按静脉氨基糖苷类使用次数分为0次(34例)、1-9次(103例)和≥10次(28例)三组。

主要发现

  • 首次检查时48%患者(平均年龄30.0岁)已有听力损失。
  • 末次检查(平均4.4年后)64%患者有听力损失,即使经年龄/性别校正。
  • 年龄/性别听力阈值校正消除了0次IVs组的阈值偏移。
  • 1-9次IVs组48%有耳毒性评分,≥10次IVs组近80%有耳毒性评分。

临床怎么用

  • 成人CF患者应规律进行听力监测,尤其多次静脉氨基糖苷类暴露者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Hearing loss is a significant and growing problem as patients with cystic fibrosis (CF) live longer and experience frequent courses of intravenous aminoglycoside antibiotics (hereafter, "IVs"). This study seeks to document that risk in a large adult population with CF, accounting for age and aminoglycoside exposure. STUDY DESIGN: Retrospective case review of patients with CF who had multiple audiograms over years. SETTING: Tertiary care cystic fibrosis setting. SUBJECT AND METHODS: The first and last audiograms recorded over a 10-year period were compared for 165 adult patients with CF. Patients were divided into 3 study groups: 34 patients with no intervening aminoglycoside IVs (0 IVs), 103 patients with 1 to 9 IVs, and 28 patients with ≥10 IVs. Threshold shift (TS) between the audiograms were examined for the 3 groups before and after age/sex adjustments. Two new hearing loss metrics were tested. RESULTS: At first examination, 48% of patients (average age, 30.0 years) already had hearing loss. At last examination (average, 4.4 years later), 64% of the patients had hearing loss even with age/sex adjustment. Use of the age/sex hearing threshold adjustment eliminated the TS in the 0 IVs group. Two new metrics calculated for each patient demonstrated that 48% of patients who had 1 to 9 IVs had ototoxic scores, while almost 80% of the ≥10 IV group had ototoxic scores. CONCLUSION: The majority of adult patients with CF are (often repeatedly) exposed to parenteral aminoglycosides and lose hearing at a rate that far exceeds that predicted from aging alone.

来源:Otolaryngol Head Neck Surg,查看原文。版权归原作者所有。

引用

  1. Zettner EM, Gleser MA. Progressive Hearing Loss among Patients with Cystic Fibrosis and Parenteral Aminoglycoside Treatment. Otolaryngol Head Neck Surg. 2018. PMID: 29914288. doi:10.1177/0194599818782444

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。